Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMD14 | O00487 | 5/20 | 1.00 |
| ▸ | COPS5 | Q92905 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | MMP2 | P08253 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | GMNN | O75496 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | MMP9 | P14780 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | MMP8 | P22894 | 1/20 | 0.61 |
| ▸ | CCR1 | P32246 | 1/20 | 0.61 |
| ▸ | THPO | P40225 | 1/20 | 0.61 |
| ▸ | MTOR | P42345 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30079755 | 1.00 | PSMD14 (1.00) | PSMD14COPS5LMNAKDM4EMMP2 | |
| Hydrochloric Acid SCHEMBL30430691 | 0.98 | PSMD14 (0.95) | PSMD14COPS5LMNAKDM4EMMP2 | |
| SCHEMBL7333832 | 0.98 | PSMD14 (0.95) | PSMD14COPS5LMNAKDM4EMMP2 | |
| SCHEMBL7431585 | 0.98 | PSMD14 (0.95) | PSMD14COPS5LMNAKDM4EMMP2 | |
| SCHEMBL1822441 | 0.98 | PSMD14 (0.95) | PSMD14COPS5LMNAKDM4EMMP2 | |
| Hydrochloric Acid SCHEMBL23648281 | 0.98 | PSMD14 (0.95) | PSMD14COPS5LMNAKDM4EMMP2 | |
| Hydrochloric Acid SCHEMBL1333579 | 0.98 | PSMD14 (0.95) | PSMD14COPS5LMNAKDM4EMMP2 | |
| SCHEMBL4819240 | 0.98 | PSMD14 (0.95) | PSMD14COPS5LMNAKDM4EMMP2 | |
| SCHEMBL9221538 | 0.98 | PSMD14 (0.95) | PSMD14COPS5LMNAKDM4EMMP2 | |
| SCHEMBL27629030 | 0.98 | PSMD14 (0.95) | PSMD14COPS5LMNAKDM4EMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 670 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4241800-B1 | ABSORBABLE IMPLANTABLE MEDICAL DEVICE MADE OF IRON-BASED ALLOY | BIOTYX MEDICAL SHENZHEN CO LTD (CN) | 2025-08-27 | — | — | EP | claimed |
| US-12208378-B1 | 1,4-divinylphenylene-bridged diruthenium complex bearing two Ru(CO) (PiPr3)2 moieties with 8-mercaptoquinolato co-ligand as an organic catalyst | King Faisal University (SA) | 2025-01-28 | — | — | US | claimed |
| CN-118703196-A | Light-activated microsphere and preparation method thereof | 深圳市帝迈生物技术有限公司 | 2024-09-27 | — | — | CN | claimed |
| WO-2024129619-A9 | STAT3 INHIBITORS FOR USE IN THE TREATMENT OF NON-VIRAL LIVER CANCER | TVARDI THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | claimed |
| WO-2024129619-A1 | STAT3 INHIBITORS FOR USE IN THE TREATMENT OF NON-VIRAL LIVER CANCER | TVARDI THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | WO | claimed |
| US-11986810-B1 | Selective reduction catalyst of α,β-unsaturated ketone using electronically weakly coupled 4,4′-divinylazoarylene-bridged diruthenium complex bearing two Ru(CO)(8-mercaptoquinolato(PiPr3)2 moieties | King Faisal University (SA) | 2024-05-21 | — | — | US | claimed |
| CN-116999680-A | Drug shock wave balloon catheter | 深圳市赛禾医疗技术有限公司 | 2023-11-07 | — | — | CN | claimed |
| EP-4241800-A2 | ABSORBABLE IMPLANTABLE MEDICAL DEVICE MADE OF IRON-BASED ALLOY | Biotyx Medical (Shenzhen) Co., Ltd. (CN) | 2023-09-13 | — | — | EP | claimed |
| WO-2023168420-A1 | COMBINATIONS OF STAT-INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS FOR THE TREATMENT AND/OR MANAGEMENT OF CANCER | TVARDI THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | WO | claimed |
| US-20230274946-A1 | ETCHING COMPOSITIONS | FUJIFILM ELECTRONIC MATERIALS U.S.A., INC. | 2023-08-31 | — | — | US | claimed |
| CN-1135420-A | Anti-counterfeiting fluorescent pressure-sensitive carbon paper and manufacturing method thereof | GEDE ANTIFAKE TECH CO NANKAI U (CN) | 1996-11-13 | — | — | CN | claimed |
| CN-1135421-A | Anti-counterfeiting fluorescent pressure-sensitive carbon paper capable of generating invisible carbon writing and manufacturing method thereof | GEDE ANTI FAKE TECH CO NANKAI (CN) | 1996-11-13 | — | — | CN | claimed |
| CN-1132696-A | Printing process of anti-forgery mark | GEDE ANTI FORGERY TECHNOLOGY C (CN) | 1996-10-09 | — | — | CN | claimed |
| CN-1117927-A | Fluorescent anti-fake mark and its making method | XINTONG SCIENCE & TECHNOLOGY C (CN) | 1996-03-06 | — | — | CN | claimed |
| US-5496491-A | FOR PHOTORESISTS, AMINE SALT REACTION PRODUCT | ASHLAND OIL COMPANY (US) | 1996-03-05 | — | — | US | claimed |
| EP-0661324-A1 | Hight-initiated cationic curable epoxyresin compositions and their use | THERA Patent GmbH & Co. KG Gesellschaft für industrielle Schutzrechte (DE) | 1995-07-05 | — | — | EP | claimed |
| EP-0403524-B1 | PREPARATION OF NITRURO COMPOUNDS USABLE AS RADIO-PHARMACEUTICAL PRODUCTS | CIS BIO INTERNATIONAL (FR) | 1993-02-10 | — | — | EP | claimed |
| EP-0403524-A1 | PREPARATION OF NITRURO COMPOUNDS USABLE AS RADIO-PHARMACEUTICAL PRODUCTS. | CIS BIO INT (FR) | 1990-12-27 | — | — | EP | claimed |
| WO-1989008657-A2 | PREPARATION OF NITRURO COMPOUNDS USABLE AS RADIO-PHARMACEUTICAL PRODUCTS | CIS BIO INTERNATONAL (FR) | 1989-09-21 | — | — | WO | claimed |
| US-3982999-A | LEUKEMIA | KHARASCH JEROME A | 1976-09-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12208378-B1 | 1,4-divinylphenylene-bridged diruthenium complex bearing two Ru(CO) (PiPr3)2 moieties with 8-mercaptoquinolato co-ligand as an organic catalyst | PIP4K2A, PIP4K2B, PIP4K2C | PSMD14 1136/4885COPS5 483/4885LMNA 4841/4885 |
| US-11986810-B1 | Selective reduction catalyst of α,β-unsaturated ketone using electronically weakly coupled 4,4′-divinylazoarylene-bridged diruthenium complex bearing two Ru(CO)(8-mercaptoquinolato(PiPr3)2 moieties | PI4K2B, DHCR24, PI4K2A | PSMD14 1814/4885COPS5 2107/4885LMNA 2677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.